SecBot SecBot
Biotech Drug Report Generated Sep 1, 2026

LX9851

LXRX·LEXICON PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating5/10
Trial phase
Phase 1
Time to market
Unknown, LX9851 is in Phase 1; if successful, approval would likely be 5-7+ years away, though as a partnered program with Novo Nordisk the timeline is at Novo Nordisk's discretion.
Why 5/10
LX9851's next hard catalyst is Phase 1 trial completion expected in Q1 2027 (~4-7 months away). This is a partnered early-stage program, not Lexicon's lead asset, the company's primary near-term value drivers are ZYNQUISTA NDA resubmission (Q4 2026) and SONATA-HCM Phase 3 topline (Q1 2027). LX9851 is a meaningful pipeline asset but not a make-or-break binary for LXRX.
Actionable Insight NEUTRAL

LX9851 is a partnered early-stage asset, the stock will primarily trade on Lexicon's nearer-term catalysts (ZYNQUISTA NDA resubmission in Q4 2026 and SONATA-HCM Phase 3 topline in Q1 2027). The next LX9851-specific catalyst is Phase 1 completion expected Q1 2027, which could trigger additional milestone payments from Novo Nordisk. Monitor for any Phase 1 data disclosures or further milestone achievements.

Price Chart

Loading chart...

Executive Summary

LX9851 is a first-in-class oral non-incretin obesity drug candidate discovered by Lexicon Pharmaceuticals (LXRX) and being developed by Novo Nordisk (NVO) under a licensing partnership. Novo Nordisk initiated a Phase 1 trial in March 2026, triggering a $10M milestone payment to Lexicon, and a third $10M milestone was earned in August 2026. Lexicon is eligible for up to $1 billion in total milestones plus tiered royalties. The Phase 1 trial (96 subjects with overweight/obesity) is expected to complete in Q1 2027. While the Novo Nordisk partnership provides validation and non-dilutive funding, LX9851 is an early-stage partnered asset and not Lexicon's primary near-term value driver, that role belongs to ZYNQUISTA (NDA resubmission Q4 2026) and SONATA-HCM (Phase 3 topline Q1 2027).

How It Works

LX9851 is a first-in-class, oral (pill-based) non-incretin drug candidate for obesity. Unlike popular GLP-1 drugs (like Ozempic/Wegovy) that mimic a natural hormone to suppress appetite and slow digestion, LX9851 works through a different biological pathway. Preclinical studies suggest it may enhance weight loss when combined with GLP-1 drugs like semaglutide, potentially offering a new oral treatment option for obesity and related metabolic disorders.

Trial Status

Phase 1 trial initiated by Novo Nordisk in March 2026, evaluating safety, tolerability, and pharmacokinetics in 96 individuals with overweight or obesity. Completion expected Q1 2027. A key Phase 1 development milestone was achieved in August 2026, triggering a third $10M milestone payment to Lexicon.

The Two-Sided Case

▲ Bull Case5
Novo Nordisk, the world's leading obesity drug developer, is developing LX9851, validating the mechanism and providing development expertise and funding.
Lexicon has already earned $20M in milestone payments (March and August 2026) and remains eligible for up to $1 billion in total milestones plus tiered royalties on future sales.
LX9851 is a first-in-class oral non-incretin candidate, a different mechanism than GLP-1s, with preclinical data showing enhanced weight loss when combined with semaglutide, suggesting potential as a combination therapy.
The Phase 1 trial is on track with completion expected Q1 2027, and the partnership structure means Lexicon bears no development costs for this program.
Analyst consensus is bullish (8 Buy/Strong Buy vs 3 Hold, 0 Sell) with a mean price target of $3.86 (41.6% upside from $2.19).
▼ Bear Case5
LX9851 is still in Phase 1, early-stage obesity drugs have a high attrition rate and most fail to reach the market.
The obesity market is intensely competitive, dominated by GLP-1-based therapies (Novo Nordisk's own Wegovy/Ozempic, Eli Lilly's Mounjaro/Zepbound). A novel non-incretin mechanism faces an uphill commercial battle even if approved.
LX9851 is partnered with Novo Nordisk, so Lexicon has no control over development pace or strategy. Lexicon's economics are limited to milestones and royalties, not full ownership.
Lexicon's stock ($2.19, near 52-week low of $1.03) faces multiple binary risks from its other pipeline programs (ZYNQUISTA NDA, SONATA-HCM) that could overshadow any LX9851 news.
Elevated short volume (67-80% of off-exchange volume in late August 2026) suggests significant bearish positioning on LXRX.

Upcoming Catalysts

  • Phase 1 trial completion expected Q1 2027
  • Potential additional milestone payments from Novo Nordisk upon achieving further development milestones
  • Any Phase 1 data disclosures or presentations at medical conferences

Source Filing

The SecBot filing or press-release report that triggered this drug report:

LEXICON PHARMACEUTICALS, INC. 8-K LXRX ·Originating report

Sources · 4

Hover a chip for the title
1 globenewswire.com2 globenewswire.com3 globenewswire.com4 sec.gov